PHARMA | PHARMANIAGA BHD

0.290 (0.0%)
0 T-O (am): 0.290 (08:59:00)
T-O (pm): 0.290 (14:29:00)
Price updated as of: 16:58
Fundamental
Technical
Total Score
PHARMA | PHARMANIAGA BHD

PHARMA Fundamental Trend

FCON: | Sharpe Ratio: | LTS:


Chart:

PHARMA Quarter Reports

Select columns required and click "Update" to save your preferences

Ann. Date Qtr. Date Q FYE Revenue [M] PBT [M] NP [M] NPM DPS EPS R. QoQ R. YoY E. QoQ E. YoY TTM
EPS		 Adj.
[M]		 NP [M]
(adj)		 NPM
(adj)		 EPS
(adj)		 E. QoQ
(adj)		 E. YoY
(adj)		 TTM EPS
(adj)
13 Nov 25 Q3 Sep 2025 3 31 Dec 2025 1,007.26 10.36 7.28 0.7% 0.00 0.28 8.7% 2.2% 83.7% 92.8%
26 Aug 25 Q2 Jun 2025 2 31 Dec 2025 926.86 7.43 3.96 0.4% 0.00 0.27 12.2% 10.6% 86.6% 41.6%
07 May 25 Q1 Mar 2025 1 31 Dec 2025 1,055.35 45.50 29.58 2.8% 0.00 2.05 13.9% 9.4% 1160.3% 15.3%
28 Feb 25 Q4 Dec 2024 4 31 Dec 2024 926.44 13.32 2.35 0.2% 0.00 0.16 10.0% 17.3% 97.7% 107.2%
26 Nov 24 Q3 Sep 2024 3 31 Dec 2024 1,029.82 138.49 101.03 9.8% 0.00 7.01 22.9% 16.3% 3512.2% 304.8%
21 Aug 24 Q2 Jun 2024 2 31 Dec 2024 838.26 3.33 2.80 0.3% 0.00 0.19 13.1% 1.2% 89.1% 42.6%
27 May 24 Q1 Mar 2024 1 31 Dec 2024 964.96 39.04 25.65 2.7% 0.00 1.78 22.2% 9.6% 178.4% 868.5%
29 Feb 24 Q4 Dec 2023 4 31 Dec 2023 789.81 -22.10 -32.72 -4.1% 0.00 -2.39 10.8% 8.4% 33.7% 94.9%
29 Nov 23 Q3 Sep 2023 3 31 Dec 2023 885.49 -56.26 -49.34 -5.6% 0.00 -3.67 4.3% 4.2% 2616.0% 672.6%
11 Aug 23 Q2 Jun 2023 2 31 Dec 2023 848.73 6.34 1.96 0.2% 0.00 0.15 3.6% 11.5% 25.9% 171.6%
18 May 23 Q1 Mar 2023 1 31 Dec 2023 880.45 9.19 2.65 0.3% 0.00 0.20 2.1% 8.5% 100.4% 90.5%
27 Feb 23 Q4 Dec 2022 4 31 Dec 2022 862.72 -638.39 -644.39 -74.7% 0.00 -49.19 6.7% 21.2% 7578.1% 853.9%
24 Nov 22 Q3 Sep 2022 3 31 Dec 2022 924.68 15.59 8.62 0.9% 0.60 0.66 21.5% 56.6% 1093.5% 82.7%
19 Aug 22 Q2 Jun 2022 2 31 Dec 2022 761.10 4.52 0.72 0.1% 0.50 0.06 20.9% 35.3% 97.4% 94.7%
20 May 22 Q1 Mar 2022 1 31 Dec 2022 962.17 37.44 27.73 2.9% 0.80 2.12 35.2% 21.3% 67.5% 19.9%
17 Feb 22 Q4 Dec 2021 4 31 Dec 2021 711.72 125.09 85.47 12.0% 5.00 6.53 66.6% 12.2% 71.5% 1450.1%
19 Nov 21 Q3 Sep 2021 3 31 Dec 2021 2,132.68 98.22 49.84 2.3% 2.00 3.81 81.2% 241.3% 263.6% 3356.0%
20 Aug 21 Q2 Jun 2021 2 31 Dec 2021 1,177.12 22.24 13.70 1.2% 1.50 1.05 48.4% 82.3% 40.8% 37.3%
21 May 21 Q1 Mar 2021 1 31 Dec 2021 793.50 31.52 23.14 2.9% 4.00 8.84 25.0% 3.2% 465.4% 3.3%
17 Mar 21 Q4 Dec 2020 4 31 Dec 2020 634.58 -13.51 -6.33 -1.0% 1.00 -2.42 1.6% 11.3% 539.0% 96.5%
19 Nov 20 Q3 Sep 2020 3 31 Dec 2020 624.80 4.09 1.44 0.2% 1.50 0.55 3.2% 12.8% 85.5% 199.8%
19 Aug 20 Q2 Jun 2020 2 31 Dec 2020 645.76 14.33 9.98 1.6% 2.50 3.82 21.2% 7.3% 55.5% 7.5%
19 May 20 Q1 Mar 2020 1 31 Dec 2020 819.92 30.88 22.40 2.7% 6.00 8.57 14.6% 4.3% 112.5% 14.2%
20 Feb 20 Q4 Dec 2019 4 31 Dec 2019 715.68 -238.47 -178.60 -24.9% 0.00 -68.45 0.2% 19.9% 37230.6% 4125.2%
20 Nov 19 Q3 Sep 2019 3 31 Dec 2019 716.85 3.88 0.48 0.1% 0.00 0.18 19.1% 23.0% 94.8% 91.1%
23 Aug 19 Q2 Jun 2019 2 31 Dec 2019 601.89 12.48 9.28 1.5% 2.50 3.56 23.4% 2.6% 52.7% 47.2%
16 May 19 Q1 Mar 2019 1 31 Dec 2019 786.11 30.24 19.62 2.5% 6.00 7.53 31.8% 28.2% 342.1% 9.6%
21 Feb 19 Q4 Dec 2018 4 31 Dec 2018 596.64 11.94 4.44 0.7% 2.00 1.71 2.4% 3.9% 17.7% 23.9%
17 Aug 18 Q2 Jun 2018 2 31 Dec 2018 582.73 11.97 5.39 0.9% 4.00 2.08 5.7% 12.5% 69.3% 43.3%
16 May 18 Q1 Mar 2018 1 31 Dec 2018 617.92 28.71 17.59 2.9% 5.00 6.77 0.8% 0.1% 19.0% 7.1%
27 Feb 18 Q4 Dec 2017 4 31 Dec 2017 613.20 19.87 21.70 3.5% 6.00 8.36 6.7% 5.2% 506.1% 2695.7%
15 Nov 17 Q3 Sep 2017 3 31 Dec 2017 574.50 15.27 3.58 0.6% 5.00 1.38 10.9% 11.5% 62.4% 72.6%
16 Aug 17 Q2 Jun 2017 2 31 Dec 2017 517.97 10.15 9.52 1.8% 4.00 3.67 16.2% 2.6% 49.7% 36.5%
16 May 17 Q1 Mar 2017 1 31 Dec 2017 618.29 27.78 18.92 3.1% 4.00 7.30 6.1% 10.6% 2363.5% 3.0%
21 Feb 17 Q4 Dec 2016 4 31 Dec 2016 582.82 4.07 -0.84 -0.1% 3.00 -0.32 13.1% 14.3% 106.4% 105.2%
21 Nov 16 Q3 Sep 2016 3 31 Dec 2016 515.22 19.92 13.06 2.5% 4.00 5.04 3.1% 1.8% 12.9% 34.6%
19 Aug 16 Q2 Jun 2016 2 31 Dec 2016 531.80 21.49 14.99 2.8% 5.00 5.79 4.9% 3.7% 18.4% 7.5%
13 May 16 Q1 Mar 2016 1 31 Dec 2016 559.20 26.54 18.38 3.3% 4.00 7.10 17.8% 18.5% 14.4% 42.2%
15 Feb 16 Q4 Dec 2015 4 31 Dec 2015 680.15 23.72 16.06 2.4% 7.00 6.20 29.7% 8.5% 19.6% 56.2%
26 Nov 15 Q3 Sep 2015 3 31 Dec 2015 524.41 25.34 19.97 3.8% 9.00 7.71 2.3% 4.5% 23.1% 33.5%
17 Aug 15 Q2 Jun 2015 2 31 Dec 2015 512.85 25.06 16.22 3.2% 7.00 6.26 8.7% 2.3% 49.0% 1.5%
18 May 15 Q1 Mar 2015 1 31 Dec 2015 471.90 38.61 31.79 6.7% 7.00 12.28 24.8% 0.7% 13.4% 21.3%
23 Feb 15 31/12/14 4 31/12/14 627.10 37.85 36.70 5.8% 12.00 14.18 24.9% 10.4% 145.4% 76.3%

PHARMA Historical Dividends

PHARMA Financial Ratios

EPS 0.66 sen
Trailing PE (Sector Median: 16.9) 44.0
PEG 44.0
Altman Z 1.7
Beaver -0.06
Current Ratio 0.92
Debt-Equity (DE) Ratio 4.57
FCF Yield -7.25 %
Revenue QoQ 8.67 %
Revenue YoY -2.19%
Profit QoQ 83.74 %
Profit YoY -92.8 %
Profit Margin (Sector Median: 5.7) 1.1 %
ROE (ROIC: 7.7) 10.13 %
Dividend Per Share (DPS) 0.0 sen
Dividend Yield (DY) 0.0 %

PHARMA Adjusted Financial Ratios

Ratios below have been recalculated after adjusting for One Off Gain/Loss detected from Quarterly reports

EPS
Trailing PE (Sector Median: 16.9)
Profit QoQ
Profit YoY
Profit Margin (Sector Median: 5.7)
ROE (ROIC: 7.25)
Altman Z

PHARMA Fair Value

Weighted Average Fair Value:

Discounted Cash Flow (DCF) 5% Growth
Discounted Cash Flow (DCF) 10% Growth
Relative Valuation
Average Analysts FV based on 2 rating(s)
Graham Formula
Graham Number
Net Tangible Asset (NTA) 0.07
Consistent QR FV
The Fair Value numbers are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The figures shown here should be taken as educational purposes only

Advanced Calculators

Calculate the fair value of the stock based on expected growth / risk, contract / award value, forecasted profit or forecasted revenue.

Forward PE FV Calculator
Latest Profit (adjusted) [M] 11.64
Expected Profit (Next QR) [M]
Expected Profit (After QR above) [M]
Expected Profit (After QR above) [M]
Estimated Fair Value
Growth/Risk Fair Value Calculator
Expected growth (%)
Estimated downside / risk (%)
Estimated New DCF Fair Value
Contract/Award Contribution Calculator
Contract/Award Value (in Million)
Estimated Contribution to Stock Price
Estimated New DCF Fair Value
Profit-Based Calculator
Expected Profit (M)
for Year
Estimated New DCF Fair Value
Revenue-Based Calculator
Expected Revenue (M)
for Year
Estimated New DCF Fair Value
Market Pricing
Expected Profit (M) 330.12
Expected Revenue (M) 31439.92
Expected Growth (%) 38.0
The Fair Value calculated using this calculators are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The purpose of this tool is to help investor to quickly calculate their own expected Fair Value based on their own research

PHARMA Directors Share Purchases (Beta)


No transaction in the last 2 months.

PHARMA Summary


Market Cap: 1901 M.

Market Cap Class: Large caps

Number of Shares: 6557 M.

Adjusted Float: 39.5%.

Stock highly correlated with

AIMFLEX (87%)

DSS (85%)

GOB (84%)

COASTAL (83%)

Pharmaniaga Berhad, through its subsidiaries, operates as an integrated healthcare company. It is engaged in the logistics and distribution; sale and marketing; and research, development, and manufacture of generic pharmaceuticals, as well as the supply of medical products and services; hospital equipping; and provision of information technology solutions. It is also involved in the sale and distribution of portable medical devices; contract manufacturing; and distribution and trade of pharmaceuticals products, food supplements, and diagnostics products. Pharmaniaga sells its products and services to the public and private sectors primarily in Malaysia and Indonesia. The company was founded in 1994 and is based in Shah Alam, Malaysia. Pharmaniaga Bhd operates as a member of UEM Group.

Sectors: Trading & Services, Healthcare, Pharmaceuticals, Vaccine, Penny Stocks

Code: 7081

Website: http://www.pharmaniaga.com/

Related Links: Bursa | Annual Report | Announcement

Warrant Info:

No warrants listed

PHARMA Top Shareholdings

Updated on 06-Jan-2026

Shareholder % Value (M)
Boustead Holdings Berhad 35.22% 669.63
Jakel Medical Sdn Bhd 14.29% 271.77
Lembaga Tabung Angkatan Tentera 10.69% 203.2
Dasar Technologies Sdn Bhd 0.74% 14.07
Lew U Sing 0.63% 11.98
Che Lodin Bin Wok Kamaruddin 0.47% 8.94
Yong Siew Yoon 0.31% 5.89
Public Gold Marketing Sdn Bhd 0.3% 5.7
Lembaga Tabung Amanah Melaka 0.27% 5.13
Poh Seng Kian 0.27% 5.13
Celeste Resources Sdn Bhd 0.23% 4.37
Ahmad Johari Bin Abdul Razak 0.23% 4.37
Teng Chi Lik 0.23% 4.37
Yayasan Lembaga Tabung Angkatan Tentera 0.23% 4.37
Agrobank Holdings Sdn Bhd 0.2% 3.8
UOB Kay Hian Pte Ltd 0.2% 3.8
Credit Suisse 0.2% 3.8
Tang & Co Sdn. Bhd. 0.18% 3.42
Maybank Investment Bank Berhad Ivt 0.16% 3.04
Celeste Assets Sdn Bhd 0.15% 2.85
Mazlan Bin Mohd Noor 0.12% 2.28
Lor Huai Yuan 0.12% 2.28
Lim Yin Peng 0.11% 2.09
Gunasekar A/L Veerappan 0.11% 2.09
Chong Tong Siew 0.11% 2.09
Mohamad Ridzuan Firdaus Maula Raja Aznin 0.11% 2.09
Syed Idrus Bin Syed Alwi 0.11% 2.09
Chiew Chieng Siew 0.1% 1.9
Lim Hua Kuang 0.09% 1.71
Ngui Kon Foh @ David Ngui Tet Shiung 0.09% 1.71
Frequently Asked Questions
Pharmaniaga Berhad, through its subsidiaries, operates as an integrated healthcare company. It is engaged in the logistics and distribution; sale and marketing; and research, development, and manufacture of generic pharmaceuticals, as well as the supply of medical products and services; hospital equipping; and provision of information technology solutions. It is also involved in the sale and distribution of portable medical devices; contract manufacturing; and distribution and trade of pharmaceuticals products, food supplements, and diagnostics products. Pharmaniaga sells its products and services to the public and private sectors primarily in Malaysia and Indonesia. The company was founded in 1994 and is based in Shah Alam, Malaysia. Pharmaniaga Bhd operates as a member of UEM Group. The company is listed on Bursa Malaysia and operates in the Trading & Services, Healthcare, Pharmaceuticals, Vaccine and Penny Stocks sectors.
Yes, PHARMANIAGA BHD is listed as Shariah-compliant.
The latest share price of PHARMANIAGA BHD is RM 0.290 updated on 27 January 2026 16:58.
As of now, PHARMANIAGA BHD has a market capitalization of 1901M based on the latest financial data.
iSaham's technical analysis indicates that PHARMANIAGA BHD's support level is at RM 0.28 and its resistance level is at RM 0.295, based on moving averages and price patterns.
The 52-week high for PHARMANIAGA BHD is RM 0.31
PHARMANIAGA BHD's share price has increased by 50.1% year-to-date, influenced by market trends and company performance.
Dividend information for PHARMANIAGA BHD has not been reported yet. Track PHARMANIAGA BHD's upcoming dividend announcements, yield changes, and payout history easily with the iSaham Stock Screener.
The main shareholders of PHARMANIAGA BHD include Boustead Holdings Berhad, Jakel Medical Sdn Bhd and Lembaga Tabung Angkatan Tentera. View more on PHARMANIAGA BHD Top Shareholders page.
You can buy PHARMANIAGA BHD shares through any licensed online broker or trading platform registered with Bursa Malaysia. If you're new to investing, iSaham can help you open an account with M+ Online, one of Malaysia's leading brokers.
When you open your M+ account through the iSaham team, you can get iSaham Pro for free as a bonus offer.
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.